Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

G ROSENBLUM

Showing results (191-200 of 243) with videos related to

Pageof 25
Sort By:
Cancer Research|August 1, 1988
Immunospecific saturable clearance mechanisms for indium-111-labeled anti-melanoma monoclonal antibody 96.5 in humansJ L Murray, L M Lamki, L J Shanken, et al.
NCI Monographs : a Publication of the National Cancer Institute|January 1, 1987
Radioimmunoimaging in malignant melanoma patients with the use of indium-111-labeled antimelanoma monoclonal antibody (ZME-018) to high-molecular-weight antigenJ L Murray, M G Rosenblum, L Lamki, et al.
Cancer|February 1, 1994
Phase II radioimmunotherapy trial with 131I-CC49 in colorectal cancerJ L Murray, D J Macey, L P Kasi, et al.
Haematologica|August 10, 2012
Phase 1 study of an anti-CD33 immunotoxin, humanized monoclonal antibody M195 conjugated to recombinant gelonin (HUM-195/rGEL), in patients with advanced myeloid malignanciesGautam Borthakur, Michael G Rosenblum, Moshe Talpaz, et al.
Neoplasia (New York, N.Y.)|October 26, 2005
The vascular-targeting fusion toxin VEGF121/rGel inhibits the growth of orthotopic human bladder carcinoma tumorsKhalid A Mohamedali, Daniel Kedar, Paul Sweeney, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|July 1, 1991
Indium-111-labeled B72.3 monoclonal antibody in the detection and staging of breast cancer: a phase I studyL M Lamki, A U Buzdar, S E Singletary, et al.
Journal of the National Cancer Institute|November 20, 1991
Clinical pharmacology, metabolism, and tissue distribution of 90Y-labeled monoclonal antibody B72.3 after intraperitoneal administrationM G Rosenblum, J J Kavanagh, T W Burke, et al.
Cancer Research|May 1, 1985
Pharmacokinetics of 111In-labeled anti-p97 monoclonal antibody in patients with metastatic malignant melanomaM G Rosenblum, J L Murray, T P Haynie, et al.
Biotherapy (Dordrecht, Netherlands)|January 1, 1989
Phase I study of cancer therapy with recombinant interleukin-2 administered by intravenous bolus injectionE M Hersh, J L Murray, W K Hong, et al.
Cancer Research|December 1, 1995
Enhanced TAG-72 expression and tumor uptake of radiolabeled monoclonal antibody CC49 in metastatic breast cancer patients following alpha-interferon treatmentJ L Murray, D J Macey, E J Grant, et al.
Pageof 25

Showing results (191-200 of 243) with videos related to

Sort By:
Pageof 25
Cancer Research|August 1, 1988
Immunospecific saturable clearance mechanisms for indium-111-labeled anti-melanoma monoclonal antibody 96.5 in humansJ L Murray, L M Lamki, L J Shanken, et al.
NCI Monographs : a Publication of the National Cancer Institute|January 1, 1987
Radioimmunoimaging in malignant melanoma patients with the use of indium-111-labeled antimelanoma monoclonal antibody (ZME-018) to high-molecular-weight antigenJ L Murray, M G Rosenblum, L Lamki, et al.
Cancer|February 1, 1994
Phase II radioimmunotherapy trial with 131I-CC49 in colorectal cancerJ L Murray, D J Macey, L P Kasi, et al.
Haematologica|August 10, 2012
Phase 1 study of an anti-CD33 immunotoxin, humanized monoclonal antibody M195 conjugated to recombinant gelonin (HUM-195/rGEL), in patients with advanced myeloid malignanciesGautam Borthakur, Michael G Rosenblum, Moshe Talpaz, et al.
Neoplasia (New York, N.Y.)|October 26, 2005
The vascular-targeting fusion toxin VEGF121/rGel inhibits the growth of orthotopic human bladder carcinoma tumorsKhalid A Mohamedali, Daniel Kedar, Paul Sweeney, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|July 1, 1991
Indium-111-labeled B72.3 monoclonal antibody in the detection and staging of breast cancer: a phase I studyL M Lamki, A U Buzdar, S E Singletary, et al.
Journal of the National Cancer Institute|November 20, 1991
Clinical pharmacology, metabolism, and tissue distribution of 90Y-labeled monoclonal antibody B72.3 after intraperitoneal administrationM G Rosenblum, J J Kavanagh, T W Burke, et al.
Cancer Research|May 1, 1985
Pharmacokinetics of 111In-labeled anti-p97 monoclonal antibody in patients with metastatic malignant melanomaM G Rosenblum, J L Murray, T P Haynie, et al.
Biotherapy (Dordrecht, Netherlands)|January 1, 1989
Phase I study of cancer therapy with recombinant interleukin-2 administered by intravenous bolus injectionE M Hersh, J L Murray, W K Hong, et al.
Cancer Research|December 1, 1995
Enhanced TAG-72 expression and tumor uptake of radiolabeled monoclonal antibody CC49 in metastatic breast cancer patients following alpha-interferon treatmentJ L Murray, D J Macey, E J Grant, et al.
Pageof 25